Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$160.40
-1.3%
$172.48
$130.96
$182.89
$283.25B0.615.66 million shs5.91 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$104.94
-1.2%
$112.00
$89.67
$121.64
$182.56B0.765.56 million shs6.15 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$129.48
-0.7%
$126.45
$99.14
$133.10
$327.98B0.398.18 million shs6.66 million shs
Novartis AG stock logo
NVS
Novartis
$99.62
+0.6%
$97.16
$92.19
$108.78
$203.62B0.531.55 million shs1.15 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.28
+1.8%
$26.92
$25.20
$40.37
$160.11B0.6343.54 million shs39.04 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-1.32%-0.82%-5.56%-8.23%+9.24%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-1.16%-1.27%-5.03%-6.66%-4.82%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.69%+0.52%+2.28%+2.27%+10.26%
Novartis AG stock logo
NVS
Novartis
+0.56%+2.18%+4.33%-1.72%-4.85%
Pfizer Inc. stock logo
PFE
Pfizer
+1.80%+4.07%+6.38%+2.61%-26.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.4111 of 5 stars
1.43.04.23.93.22.51.9
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9892 of 5 stars
3.35.04.24.52.22.52.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.6785 of 5 stars
2.33.03.34.13.22.51.9
Novartis AG stock logo
NVS
Novartis
3.1297 of 5 stars
2.05.02.50.02.60.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9917 of 5 stars
4.23.04.24.83.71.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.318.67% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.67
Moderate Buy$121.5015.78% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.331.43% Upside
Novartis AG stock logo
NVS
Novartis
2.00
Hold$115.0015.44% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0027.32% Upside

Current Analyst Ratings

Latest MRK, NVS, ABT, PFE, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/26/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$142.00 ➝ $143.00
4/24/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$124.00
4/24/2024
Novartis AG stock logo
NVS
Novartis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
4/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$141.00 ➝ $140.00
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.40B5.21$15.48 per share10.36$5.78 per share27.75
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.55$6.30 per share16.65$22.36 per share4.69
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.46$3.09 per share41.91$14.85 per share8.72
Novartis AG stock logo
NVS
Novartis
$45.44B4.48$11.39 per share8.75$22.87 per share4.36
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.74$3.03 per share9.34$15.81 per share1.79

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3747.6013.302.0711.02%165.18%14.40%7/25/2024 (Estimated)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2132.6920.502.5513.96%20.18%10.60%7/18/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.90143.8713.071.633.76%14.15%5.24%8/6/2024 (Estimated)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.4113.4412.241.5631.33%32.15%13.59%7/16/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.281.17-0.56%8.58%3.70%8/6/2024 (Estimated)

Latest MRK, NVS, ABT, PFE, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/3/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion      
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/25/2024Q1 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.94$2.07+$0.13$2.27$15.21 billion$15.78 billion    
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.87%+7.84%183.98%52 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.10%+12.31%68.54%53 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.38%+6.08%342.22%13 Years
Novartis AG stock logo
NVS
Novartis
$2.432.44%+4.26%32.79%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.685.94%+2.57%N/A 15 Years

Latest MRK, NVS, ABT, PFE, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.11
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Novartis AG stock logo
NVS
Novartis
0.43
0.90
0.71
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.47%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.04 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

MRK, NVS, ABT, PFE, and ABBV Headlines

SourceHeadline
Pfizer: A 6% Yield And At 10-Year LowsPfizer: A 6% Yield And At 10-Year Lows
seekingalpha.com - May 8 at 11:45 PM
Cullen Frost Bankers Inc. Has $15.63 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)Cullen Frost Bankers Inc. Has $15.63 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 8 at 10:38 PM
Pfizer (NYSE:PFE) Halts Gene Therapy Trial After Patient DeathPfizer (NYSE:PFE) Halts Gene Therapy Trial After Patient Death
msn.com - May 8 at 6:45 PM
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug ZantacPfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
msn.com - May 8 at 6:45 PM
Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reportsPfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
finance.yahoo.com - May 8 at 6:45 PM
UPDATE 1-Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reportsUPDATE 1-Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
finance.yahoo.com - May 8 at 6:45 PM
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call TranscriptOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 8 at 6:45 PM
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This Massive Upside?Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
finance.yahoo.com - May 8 at 6:45 PM
Second Death - Pfizer Reports Young Boys Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder TrialSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
finance.yahoo.com - May 8 at 6:45 PM
Pfizer (NYSE:PFE) Stock Price Up 0.8%Pfizer (NYSE:PFE) Stock Price Up 0.8%
marketbeat.com - May 8 at 5:29 PM
Traders Buy High Volume of Pfizer Call Options (NYSE:PFE)Traders Buy High Volume of Pfizer Call Options (NYSE:PFE)
marketbeat.com - May 8 at 4:27 PM
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancerPfizer agrees to settle over 10K lawsuits linking Zantac to cancer
nypost.com - May 8 at 11:57 AM
Heres why you should buy these 3 stocks and hold them foreverHere's why you should buy these 3 stocks and hold them forever
finbold.com - May 8 at 9:38 AM
Pfizer Halts Dosing in Late-Stage DMD Study Following Death of Young PatientPfizer Halts Dosing in Late-Stage DMD Study Following Death of Young Patient
biospace.com - May 8 at 8:32 AM
Got $1,000? 3 Dividend Stocks to Buy and Hold ForeverGot $1,000? 3 Dividend Stocks to Buy and Hold Forever
fool.com - May 8 at 7:16 AM
Pfizer reports young patient death in Duchenne gene therapy trialPfizer reports young patient death in Duchenne gene therapy trial
newshub.co.nz - May 8 at 3:32 AM
UPDATE 2-Pfizer reports patient death in Duchenne gene therapy studyUPDATE 2-Pfizer reports patient death in Duchenne gene therapy study
finance.yahoo.com - May 7 at 10:31 PM
Pfizer reports patient death in Duchenne gene therapy studyPfizer reports patient death in Duchenne gene therapy study
reuters.com - May 7 at 5:04 PM
Pfizer (NYSE:PFE) Trading Up 0.5%Pfizer (NYSE:PFE) Trading Up 0.5%
marketbeat.com - May 7 at 3:52 PM
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareBiotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
investorplace.com - May 7 at 2:04 PM
Is Pfizer Stock Fully Valued At $28?Is Pfizer Stock Fully Valued At $28?
forbes.com - May 7 at 12:30 PM
Pfizer First Quarter 2024 Earnings: Beats ExpectationsPfizer First Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - May 7 at 12:30 PM
Pfizer: Solid Earnings, But Were Not Out Of The Woods YetPfizer: Solid Earnings, But We're Not Out Of The Woods Yet
seekingalpha.com - May 7 at 4:32 AM
Welch & Forbes LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)Welch & Forbes LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 7 at 12:17 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Novartis logo

Novartis

NYSE:NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.